Insider Buying: CalciMedica, Inc. (NASDAQ:CALC) Major Shareholder Acquires 86,867 Shares of Stock

CalciMedica, Inc. (NASDAQ:CALC) major shareholder Sanderling Venture Partners Vi acquired 86,867 shares of the stock in a transaction on Friday, November 1st. The stock was bought at an average cost of $3.75 per share, for a total transaction of $325,751.25. Following the transaction, the insider now owns 814,300 shares of the company’s stock, valued at approximately $3,053,625. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

CalciMedica Price Performance

CalciMedica stock traded up $0.04 during trading hours on Tuesday, hitting $3.54. The company had a trading volume of 73,214 shares, compared to its average volume of 34,919. The firm has a 50-day moving average of $4.24 and a 200 day moving average of $4.63. The firm has a market cap of $38.06 million, a PE ratio of -2.53 and a beta of 1.30. CalciMedica, Inc. has a one year low of $2.68 and a one year high of $8.38.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. As a group, research analysts expect that CalciMedica, Inc. will post -2.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CALC has been the subject of a number of research analyst reports. HC Wainwright cut their price objective on CalciMedica from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Monday. Oppenheimer increased their price target on shares of CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, July 10th.

Institutional Trading of CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Atria Investments Inc lifted its holdings in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,503 shares of the company’s stock after buying an additional 15,296 shares during the period. Atria Investments Inc owned approximately 0.25% of CalciMedica worth $117,000 at the end of the most recent quarter.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.